|
|
||||||||
1 Dept of Orthopaedics, Malmö University Hospital, Malmö, Sweden. 2 Dept of Respiratory Diseases, Ghent University Hospital, Ghent, Belgium. 3 Dept of Respiratory Medicine, University Hospital, Lund, Sweden. 4 Dept of Medicine, University Central Hospital, Helsinki, Finland. 5 Division of Respiratory Disease, University Hospital, Groningen, the Netherlands. 6 Respiratory Division, Imperial College School of Medicine, Hammersmith Hospital, London, UK. 7 AstraZeneca, Lund, Sweden
CORRESPONDENCE: O. Johnell, Dept of Orthopaedics, UMAS, S-205 02 Malmö, Sweden. Fax: 46 40336227. E-mail: olof.Johnell@orto.mas.lu.se
Keywords: bone mineral density, budesonide, chronic obstructive pulmonary disease, drug safety, fractures, inhaled steroids
Received: August 28, 2001
Accepted December 27, 2001
This study was supported by AstraZeneca Research and Development Lund, Lund, Sweden.
There is a need for studying the effects of long-term inhaled corticosteroid therapy on bone mineral density (BMD) and vertebral fracture rates in patients with mild chronic obstructive pulmonary disease (COPD).
Patients (n=912, mean age 52 yrs) with mild COPD (mean forced expiratory volume in one second (FEV1) 77% of predicted; mean FEV1/slow vital capacity ratio 62%) were randomized to receive budesonide 400 µg, or placebo twice daily via Turbuhaler®. BMD was measured at the L2L4 vertebrae and the femoral neck, trochanter and Ward's triangle by dual-energy X-ray absorptiometry at baseline and after 6, 12, 24 and 36 months (n=161). Radiographs of the thoracic and lumbar spine were obtained at the beginning and end of treatment (n=653).
Previous fractures were present at baseline in 43 budesonide-treated patients (13.4%) and 38 placebo-treated patients (11.5%). New fractures occurred in five budesonide-treated patients, compared with three in the placebo group (p=0.50). There were no significant changes in BMD at any site in budesonide-treated patients, compared with the placebo group, during the course of the study. Budesonide treatment was associated with a slight but statistically significant decrease in the area under the concentration-time curve for serum osteocalcin.
In the present study, involving a large group of patients with chronic obstructive pulmonary disease, long-term treatment with budesonide 800 µg·day1 via Turbuhaler® had no clinically significant effects on bone mineral density or fracture rates.
This article has been cited by other articles:
![]() |
S. Suissa, R. McGhan, D. Niewoehner, and B. Make Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 535 - 542. [Abstract] [Full Text] [PDF] |
||||
![]() |
C-G. Lofdahl, D. S. Postma, N. B. Pride, J. Boe, and A. Thoren Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD Eur. Respir. J., June 1, 2007; 29(6): 1115 - 1119. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gartlehner, R. A. Hansen, S. S. Carson, and K. N. Lohr Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes Ann. Fam. Med, May 1, 2006; 4(3): 253 - 262. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.M. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, S. Peterson, and H. Olsson Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease Eur. Respir. J., December 1, 2003; 22(6): 912 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Sin, F. A. McAlister, S. F. P. Man, and N. R. Anthonisen Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review JAMA, November 5, 2003; 290(17): 2301 - 2312. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Szafranski, A. Cukier, A. Ramirez, G. Menga, R. Sansores, S. Nahabedian, S. Peterson, and H. Olsson Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur. Respir. J., January 1, 2003; 21(1): 74 - 81. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |